A Comprehensive Approach To Relief Of Digestive Symptoms In Cystic Fibrosis: CARDS-CF

Completed

• Conditions: Pancreatic Disease; Genetic Disease; Cystic Fibrosis; Lung Diseases; Digestive System Disease; Respiratory Tract Diseases
• Interventions: Other: Focus group; Other: Patient interview (n = approximately 10); Other: Questionnaire (n = 180); Device: Testing of the pilot PROM in a smartphone app (n = 150)

• Registration Number: NCT05251467
• Lead Sponsor: Nottingham University Hospitals NHS Trust

Brief Summary

Development of a new patient reported outcome measure (PROM) that will measure the daily burden of gastrointestinal symptoms over the previous 24 hour period for people with cystic fibrosis.

Detailed Description

Development of a Patient Reported Outcome Measure (PROM) in line with FDA guidance. The PROM is intended for daily use to measure the symptom burden of gastrointestinal symptoms for people with CF over the last 24 hours.

* Development of the initial conceptual framework underpinning the PROM and confirmed through a patient focus group.

* Primary item (question) generation for the PROM which will then be refined through a series of interviews with people with CF.

* Testing of the items through an online patient questionnaire for testing of frequency, burden and impact of the items.

* Piloting testing of the draft PROM daily for 2 weeks via smartphone app. The recall period of the PROM will be gastrointestinal symptom burden over the previous 24 hours.

Potential participant's will be identified through 6 UK CF care centres at Nottingham University Hospitals NHS Trust (paediatric and adult CF centres), Leeds Teaching Hospital NHS Trust, Manchester University NHS Foundation trust, Royal Brompton and Harefield NHS Foundation Trust and Kings College Hospital NHS Foundation Trust. In addition, recruitment for the survey and trialing the PROM on a smartphone app will also take place via social media and is therefore also open to people with CF from outside these CF centres.

Study Timeline

• Study First Submitted: 2022-02-04
• Study First Submitted QC: 2022-02-11
• Study First Posted: 2022-02-22
• Study Start: 2022-02-28
• Primary Completion: 2023-12-03
• Study Completion: 2023-12-03
• Status Verified: 2024-07
• Last Update Submitted: 2024-07-18
• Last Update Posted: 2024-07-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 350

Inclusion Criteria

• People with cystic fibrosis age 12 years and over
• Confirmed diagnosis of cystic fibrosis based on genotype or sweat chloride testing
• Capacity to consent, or to understand the requirements of the study where parental consent is required

Exclusion Criteria

• < 12 years age
• Unable to give informed consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
People with CF age 12 years and over	Focus group	Participants will be identified through one of the 6 participating UK CF centres as well as recruiting via social media. Participants outside the 6 listed CF centres as well as outside the UK are also eligible.
People with CF age 12 years and over	Patient interview (n = approximately 10)	Participants will be identified through one of the 6 participating UK CF centres as well as recruiting via social media. Participants outside the 6 listed CF centres as well as outside the UK are also eligible.
People with CF age 12 years and over	Questionnaire (n = 180)	Participants will be identified through one of the 6 participating UK CF centres as well as recruiting via social media. Participants outside the 6 listed CF centres as well as outside the UK are also eligible.
People with CF age 12 years and over	Testing of the pilot PROM in a smartphone app (n = 150)	Participants will be identified through one of the 6 participating UK CF centres as well as recruiting via social media. Participants outside the 6 listed CF centres as well as outside the UK are also eligible.

Primary Outcome Measures

Name	Time	Method
To develop a new patient reported outcome measure (PROM) which will measure the daily gastrointestinal symptom burden for people with CF, with a recall period of 24 hours.	2 years	Development of a new PROM following FDA guidance which will measure the daily impact and burden of gastrointestinal symptoms for people with CF. The recall period will be the previous 24 hours. The name of the PROM will be decided as part of the development process. Question development will be iterative. Floor and ceiling effects for each of the questions will be assessed. The CFAbd score will be used to assess construct validity of the newly developed PROM. This will be completed alongside the PROM on days 1 and day 14.

Secondary Outcome Measures

Name	Time	Method
Attrition rate of participants	2 years	Attrition rate over the 2 weeks, define as people completing the app for two weeks (at least 10 out of 14 days) as a percentage of those initially who gave consent to take part and use the app.
Measurement of adherence to daily data capture of the PROM through a smartphone app over a 2 week period	2 years	Adherence data - Percentage of completed PROM days over the 14 day period. Percentage of completed CFabd scores on days 1 and 14. This data will be collated through the research portal feedback facility in the app.
Usability of the smartphone app	2 years	Usability of the app - participant feedback via the app on days 7 and 14 to include questions of ease of data entry on the app, whether they experience any technical issues with the app and whether questions are meaningful to participants. These questions will be developed as part of the PROM development process.

Trial Locations

Locations (1)

Nottingham University Hospitals NHS Trust; 🇬🇧 Nottingham, United Kingdom